H. Lundbeck 将来の成長

Future 基準チェック /16

H. Lundbeck利益と収益がそれぞれ年間8.6%と3.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に10.5% 8.8%なると予測されています。

主要情報

8.6%

収益成長率

8.8%

EPS成長率

Pharmaceuticals 収益成長	20.3%
収益成長率	3.7%
将来の株主資本利益率	10.5%
アナリストカバレッジ	Good
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:LDBA - アナリストの将来予測と過去の財務データ ( )DKK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	24,638	4,074	5,156	5,624	9
12/31/2025	23,339	3,581	4,774	5,183	10
12/31/2024	22,053	3,039	4,316	4,689	9
9/30/2024	21,441	2,687	4,936	5,421	N/A
6/30/2024	20,671	2,586	4,128	4,609	N/A
3/31/2024	20,239	2,298	4,245	4,791	N/A
12/31/2023	19,912	2,290	3,579	4,080	N/A
9/30/2023	19,614	2,467	3,528	4,426	N/A
6/30/2023	19,381	2,479	3,523	4,457	N/A
3/31/2023	18,918	2,384	3,292	4,102	N/A
12/31/2022	18,246	1,916	2,699	3,519	N/A
9/30/2022	17,619	1,603	2,051	2,615	N/A
6/30/2022	16,913	1,236	1,744	2,313	N/A
3/31/2022	16,398	1,109	1,344	1,959	N/A
12/31/2021	16,299	1,318	1,660	2,272	N/A
9/30/2021	16,521	1,873	2,405	2,949	N/A
6/30/2021	16,971	1,965	2,379	2,912	N/A
3/31/2021	17,381	2,110	3,263	3,757	N/A
12/31/2020	17,672	1,581	3,359	3,837	N/A
9/30/2020	17,818	904	2,713	3,171	N/A
6/30/2020	17,490	1,242	2,910	3,354	N/A
3/31/2020	17,366	1,507	1,502	1,960	N/A
12/31/2019	17,036	2,313	2,165	2,609	N/A
9/30/2019	16,811	3,091	3,210	3,621	N/A
6/30/2019	17,309	3,395	2,736	3,462	N/A
3/31/2019	17,766	3,606	4,100	4,815	N/A
12/31/2018	18,117	3,907	5,277	5,981	N/A
9/30/2018	18,313	3,806	5,057	5,922	N/A
6/30/2018	18,028	3,627	N/A	6,197	N/A
3/31/2018	17,608	3,236	N/A	5,397	N/A
12/31/2017	17,234	2,624	N/A	4,045	N/A
9/30/2017	17,007	2,544	N/A	3,731	N/A
6/30/2017	16,607	1,988	N/A	3,551	N/A
3/31/2017	16,075	1,612	N/A	3,420	N/A
12/31/2016	15,634	1,211	N/A	3,126	N/A
9/30/2016	15,202	290	N/A	4,158	N/A
6/30/2016	14,923	-1,289	N/A	2,755	N/A
3/31/2016	14,801	-5,427	N/A	936	N/A
12/31/2015	14,594	-5,694	N/A	197	N/A
9/30/2015	14,108	-5,879	N/A	-1,330	N/A
6/30/2015	13,625	-4,615	N/A	-464	N/A
3/31/2015	13,444	-565	N/A	1,379	N/A
12/31/2014	13,468	-153	N/A	1,610	N/A
9/30/2014	13,808	503	N/A	2,601	N/A
6/30/2014	14,181	765	N/A	2,095	N/A
3/31/2014	14,269	119	N/A	2,982	N/A
12/31/2013	15,258	855	N/A	3,760	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LDBAの予測収益成長率 (年間8.6% ) は貯蓄率 ( 1% ) を上回っています。

収益対市場: LDBAの収益 ( 8.6% ) German市場 ( 20.8% ) よりも低い成長が予測されています。

高成長収益: LDBAの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: LDBAの収益 ( 3.7% ) German市場 ( 5.6% ) よりも低い成長が予測されています。

高い収益成長: LDBAの収益 ( 3.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LDBAの自己資本利益率は、3年後には低くなると予測されています ( 10.5 %)。

H. Lundbeck 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023)

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr.1.01 (vs kr.0.89 in 1Q 2023)

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Dividend of kr.0.70 announced

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘